(TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company ...
Cash balance of $116 million as of June 30, 2026 expected to fund operations through the end of 2028, supporting anticipated ...
Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization ...
About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of ...
Oxford Brain Diagnostics (OBD), a pioneer in quantitative brain biology, today announced new research demonstrating that its ...
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous ...
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 9, 2026
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to ...
Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomized Phase II ...
Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results